Related Experiment Video

Updated: May 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Therapeutic use of an anti-ErbB3 monoclonal antibody

Na Li1, Yanchun Yang

  • 1Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Hybridoma (2005)
|June 30, 2012
PubMed

Insights

Researchers developed a specific antibody targeting the ErbB3 (HER3) protein, crucial in cancer and mental disorders. This novel antibody shows high affinity and potential for disease diagnosis and therapy.

Area of Science:

  • Oncology
  • Neuroscience
  • Immunology

Background:

  • The ErbB3 (HER3) protein, though catalytically inactive, is implicated in tyrosine kinase receptor signaling.
  • Aberrant ErbB3 signaling is linked to human cancers and certain mental disorders, such as schizophrenia.
  • Targeting ErbB3 presents a potential strategy for disease intervention.

Purpose of the Study:

  • To generate a specific monoclonal antibody (MAb) against the ErbB3 protein.
  • To characterize the generated anti-ErbB3 antibody for potential diagnostic and therapeutic applications.

Main Methods:

  • Hybridoma technique was employed to generate antibody-producing cell lines.
  • Characterization included determining molecular weight, isotype (IgG 2a and κ), and affinity constant (Kaff).

Main Results:

  • A stable hybridoma cell line (2E(12)C(3)) producing anti-ErbB3 antibody was successfully established.
  • The antibody has a molecular weight of approximately 185 kDa.
  • The anti-ErbB3 MAb exhibited a high affinity constant (Kaff) of 5.83×10^10 M⁻¹.

Conclusions:

  • The generated anti-ErbB3 antibody is a specific and high-affinity tool.
  • This antibody holds promise for diagnostic applications in ErbB3-expressing cancers.
  • Potential therapeutic applications and utility in understanding schizophrenia etiology are suggested.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.